A REVIEW ON USE OF TOCILIZUMAB FOR THE TREATMENT OF COVID-19
European Journal of Molecular & Clinical Medicine,
2020, Volume 7, Issue 7, Pages 5752-5757
AbstractAlthough a viral infection begins in COVID-19, some patients have overly exuberant inflammation, leading to acute pulmonary injury and a condition of adult respiratory distress (ARDS). As IL-6 is a key role in the inflammatory response, in this single centre observatory study in all Covid-19 patients with a proven SARS-CoV-2 fast-pacing infection in order to escape ALI and ARDS we have assessed the effectiveness and protection of tocilizumab (TCZ). In this single centre The rate of mortality in 104 patients treated for COVID-19 was lower (5 · 8%). The percentage of patients treated with COVID-19 was 11% lower than in untreated patients who had our level of treatment alone and a marginally lower rate of mortality (6 percent ). The acute phase reagents, Ferritin, and liver protein releases were quickly diminished by TCZ. Slowly, D-Dimer declined. Relevant safety issues were not found. An early prescribing of IL6-R antagonists can be safe and successful for avoidance, ICU admission and more complications in COVID-19 patients with imminent hyperinflammatory reaction1.
- Article View: 147
- PDF Download: 255